Document is current
Any future updates will be listed below
-
Authors
,
Klarin, Derek https://orcid.org/0000-0002-4636-5780
,
Busenkell, Emma
Judy, Renae
Lynch, Julie https://orcid.org/0000-0003-0108-2127
Levin, Michael https://orcid.org/0000-0002-9937-9932
Haessler, Jeffery
Aragam, Krishna
Chaffin, Mark https://orcid.org/0000-0002-1234-5562
Haas, Mary
Lindström, Sara
Assimes, Themistocles L. https://orcid.org/0000-0003-2349-0009
Huang, Jie
Min Lee, Kyung https://orcid.org/0000-0001-8995-0448
Shao, Qing
Huffman, Jennifer E. https://orcid.org/0000-0002-9672-2491
Kabrhel, Christopher
Huang, Yunfeng
Sun, Yan V.
Vujkovic, Marijana https://orcid.org/0000-0003-4924-5714
Saleheen, Danish
Miller, Donald R.
Reaven, Peter
DuVall, Scott
Boden, William E.
Pyarajan, Saiju
Reiner, Alex P.
Trégouët, David-Alexandre
Henke, Peter
Kooperberg, Charles
Gaziano, J. Michael
Concato, John
Rader, Daniel J.
Cho, Kelly
Chang, Kyong-Mi
Wilson, Peter W. F.
Smith, Nicholas L.
O’Donnell, Christopher J.
Tsao, Philip S. https://orcid.org/0000-0001-7274-9318
Kathiresan, Sekar https://orcid.org/0000-0002-6724-032X
Obi, Andrea
Damrauer, Scott M. https://orcid.org/0000-0001-8009-1632
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K08HL140203, R01HL142711, R01HL127564, HL116854)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Veterans Affairs (I01-01BX03340, I01-BX003362, I01-01BX03340, I01-CX001025, I01-BX003362, IK2-CX001780)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 5 March 2019
Accepted: 24 September 2019
First Online: 1 November 2019
Competing interests
: P.N. reports grant support from Amgen, Apple and Boston Scientific, and consulting income from Apple, all unrelated to the submitted work. S.K. reports grant support from Regeneron Pharmaceuticals and Bayer, grant support and personal fees from Aegerion Pharmaceuticals, personal fees from the Regeneron Genetics Center, Merck, Celera Corporation, Novartis, Bristol-Myers Squibb, Sanofi, AstraZeneca, Alnylam Pharmaceuticals, Eli Lilly and Company and Leerink Partners, personal fees and other support from Catabasis and other support from San Therapeutics outside the submitted work. He is also the chair of the scientific advisory board at Genomics plc and the Chief Executive Officer of Verve Therapeutics. S.D. reports grants to his institution in the last 3 years outside the submitted work: AbbVie Inc.; Anolinx LLC; Astellas Pharma Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Genomic Health, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Innocrin Pharmaceuticals Inc.; Janssen Pharmaceuticals; Kantar Health; Myriad Genetic Laboratories, Inc.; Novartis International AG; and Parexel International Corporation. C.K. reports grants to his institution from Janssen Pharmaceuticals, Diagnostica Stago and Siemens Healthcare Diagnostics for research related to VTE, but not related to the current work. J.C. is now with the US Food and Drug Administration.
